Dorzolamide

Dorzolamide
Clinical data
Trade names	Trusopt, others
AHFS/Drugs.com	Monograph
MedlinePlus	a602022
Routes of; administration	eye drops
ATC code	S01EC03 (WHO) S01EE52 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Protein binding	~33%
Elimination half-life	4 months
Identifiers
	IUPAC name (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide;
CAS Number	120279-96-1 ; HCl: 130693-82-2 ;
PubChem CID	5284549;
IUPHAR/BPS	6810;
DrugBank	DB00869 ;
ChemSpider	4447604 ;
UNII	9JDX055TW1; HCl: QZO5366EW7 ;
KEGG	D07871 ;
ChEBI	CHEBI:4702 ;
ChEMBL	ChEMBL218490 ;
CompTox Dashboard (EPA)	DTXSID7022960 ;
ECHA InfoCard	100.229.271
Chemical and physical data
Formula	C10H16N2O4S3
Molar mass	324.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCNC1CC(C)S(=O)(=O)c2sc(cc12)S(=O)(=O)N;
	InChI InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1 ; Key:IAVUPMFITXYVAF-XPUUQOCRSA-N ;
	(what is this?) (verify)

Dorzolamide, sold under the brand name Trusopt among others, is a medication used to treat high pressure inside the eye, including in cases of glaucoma. It is used as an eye drop. Effects begin within three hours and last for at least eight hours. It is also available as the combination dorzolamide/timolol.

Common side effects include eye discomfort, eye redness, taste changes, and blurry vision. Serious side effects include Steven Johnson syndrome. Those allergic to sulfonamides may be allergic to dorzolamide. Use is not recommended in pregnancy or breastfeeding. It is a carbonic anhydrase inhibitor and works by decreasing the production of aqueous humor.

Dorzolamide was approved for medical use in the United States in 1994. It is available as a generic medication. In 2022, it was the 201st most commonly prescribed medication in the United States, with more than 2 million prescriptions.